secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001213900-23-007404
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive licenses Renazorb to Lotus for Korea; $0.75M upfront, up to $4.45M milestones
--------------------------------------------------------------------------------

- Exclusive license to Lotus for Renazorb in Republic of Korea; Lotus handles development, registration, importation, and commercialization costs.
- Unicycive receives $750,000 upfront and up to $4.45M in regulatory/commercial milestones plus tiered royalties.
- Renazorb is a phosphate binding agent for hyperphosphatemia in CKD patients; this is Unicycive's second Asian partnership.
- Lotus has nephrology presence in Korea via Alvogen Korea with 45% market share for Epoetin (IQVIA 3Q 2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023007404/0001213900-23-007404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023007404/ea172614-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-007404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer